The cold chain: why some medicines need refrigeration from factory to pharmacy

The journey of a medicine from the manufacturing plant to the patient is a complex logistical process. For many pharmaceutical products, this journey must take place within the 'cold chain'—a continuous series of temperature-controlled storage and distribution steps. Maintaining a specific temperature range, commonly between 2°C and 8°C, is essential to preserve the safety and effectiveness of certain medicines. If these products are exposed to heat or freezing temperatures, their chemical structures can change, potentially rendering them inactive or unsafe. The cold chain encompasses every step of the supply chain, including transport vehicles, warehouses, distribution centres, and pharmacy fridges.

Temperature control is not just about keeping things cold; it is about maintaining stability. A break in the cold chain, even a brief one, can permanently alter a medicine's formulation. Consequently, pharmaceutical companies and healthcare systems invest heavily in infrastructure to ensure that temperature-sensitive products remain within their approved limits until they are ready to be dispensed to the patient.

Which medicines require temperature control?

Temperature-sensitive medicines are generally those derived from biological sources or containing complex, unstable molecules. Vaccines are the most well-known cold-chain products; their active ingredients, often weakened viruses or proteins, are highly sensitive to heat. Biologics, including monoclonal antibodies and insulin, also require strict temperature management. Because these medicines are made from living organisms or large proteins, heat causes them to denature—a process where the protein unfolds and loses its therapeutic properties.

In addition to biologics, certain liquid formulations such as some antibiotic suspensions, eye drops, and specific blood products must be kept cool to prevent bacterial growth and chemical degradation. Some advanced chemical drugs, such as certain targeted cancer therapies, are also assigned cold-chain status due to their specific molecular fragility. Solid tablets, by contrast, can usually tolerate ambient temperatures, which is why the cold chain applies to a specific but vital subset of the global pharmaceutical market.

How the cold chain is monitored

Keeping a product at 2°C to 8°C from factory to pharmacy requires continuous monitoring and specialised equipment. Cold-chain shipments typically use refrigerated trucks, insulated containers, and gel packs. Inside these containers, electronic data loggers record the temperature throughout the journey, providing a detailed history that pharmacists can review upon arrival. Some systems even use GPS tracking to ensure that a vehicle's route does not introduce unexpected delays.

For vaccines, the World Health Organization (WHO) endorses the use of Vaccine Vial Monitors (VVMs)—small heat-sensitive labels on vaccine vials that change colour irreversibly when exposed to cumulative heat. This allows healthcare workers to see at a glance whether a vaccine is still safe to use. To prevent the risk of freezing, which can also damage sensitive medicines, many modern cold-chain systems use cloud-connected sensors that trigger alarms if temperatures fall below 2°C or rise above 8°C, allowing for immediate corrective action.

Implications for access in hot climates

Maintaining the cold chain presents significant logistical challenges, particularly in hot climates or regions with unreliable electricity. In many parts of the world, ambient temperatures frequently exceed 30°C, making refrigeration essential but difficult to sustain. Transport over long distances on poor roads can lead to delays and temperature excursions. The 'last mile' of delivery—moving medicines from a regional store to a rural clinic—is often the most vulnerable point in the chain.

To address this, global health organisations have developed innovative solutions such as solar-powered refrigerators and passive cooling devices that can maintain temperatures for several days without electricity. Despite these innovations, cold-chain failures remain a major barrier to medicine access. When a batch of vaccines or insulin is compromised by heat, it must be discarded, leading to stockouts and delayed treatment. These challenges disproportionately affect low- and middle-income countries, where infrastructure limitations can complicate the delivery of temperature-sensitive medicines to remote populations.

Regulatory oversight and the patient

Because temperature exposure directly impacts whether a medicine works, regulators strictly enforce cold-chain compliance. Good Distribution Practices (GDP) are international guidelines that dictate how medicines should be stored and transported to ensure quality is maintained. In South Africa, the South African Health Products Regulatory Authority (SAHPRA) requires wholesalers and pharmacies to adhere to these standards, ensuring that medicines registered for use remain stable. When searching for a medicine on HealthSA, patients can be assured that the Single Exit Price applies to the product itself, but the pharmacy is responsible for maintaining its quality up to the point of dispensing.

Ultimately, a well-maintained cold chain is an invisible but essential component of modern healthcare. It ensures that the medicines patients receive are as safe and effective as the day they were manufactured, regardless of how far they have travelled or how hot it is outside.